Hirst GL, Coppe JP, Kok M, Sonke GS, van 't Veer LJ, Horlings HM. B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of ...
1.Abbasvandi F, Bayat M, Akbari A, Shojaeian F, Zandi A, Rahmani J, Hashemi MO, Akbari ME. Tumor characteristics and survival rate of HER2-low breast cancer patients: a retrospective cohort study. Sci Rep. 2023 Oct 4;13(1):16719. doi: 10.1038/s41598-023-43186-8. PMID: 37794050; ...
Padeano MM, Costaz H, Amet A, Coutant C, Coudert B, Bertaut A, Ladoire S. Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy. Breast Cancer
[8]Wong Y,Raghavendra AS,Hatzis C,et al.Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2(HER2)Positive Breast Cancers Treated with HER2-Targeted Therapy.Oncologist.2019 Mar;24(3):313-318. [9]Yardley DA,Tripathy D,Brufsky AM,et al.Long-term survivor characteristics ...
[5] Eggemann H, Ignatov T, Burger E et al (2015) Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer. Endocr Relat Cancer 22:725–733. [6] Howlader N, Cronin KA, Kurian AW et al (2018) Differences in breast cancer survival by molecular subtypes in...
[12] Saura C, Modi S, Ian Krop I,et al.Trastuzumab Deruxtecan (T-DXd)in Patients with HER2-Positive Metastatic Breast Cancer: Updated Survival Results from a Phase 2 Trial (DESTINY-Breast01).2021 ESMO. 279P. [13] Brasó-Maristany F, Griguolo G, Chic N, et al. HER2DX genomic as...
[6] Slamon D J, Clark G M, Wong S G, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene[J]. science, 1987, 235(4785): 177-182. [7] Wieduwilt M J, Moasser M M. Theepidermalgrowth factor receptor family: biology driving...
[3]. Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): Updated survival results of DESTINY-Breast03. 2024 ASCO. 1025. [4]. Modi, S., Jacot, W., Yamashita, T., et al. DESTINY-Breast04 Trial Investigators (...
[1] Erika P. Hamilton, et al. Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): Updated survival results of DESTINY-Breast03.2024 ASCO 1025P. [2] Cristina Saura, et al. Pooled analysis by best confirmed response...
Breast cancer-specific survival in patients with HER2-positive, node-negative T1a and T1b breast cancer ☆Within this large cohort of T1a/b N0 breast cancers from the CCR, HER2+ tumors were associated with a significantly worse BCSS in the era before adjuvant trastuzumab. A balanced discussion...